RNA Advisors, LLC, a leading valuation and strategic advisory services firm focused exclusively in life sciences and healthcare technology, announced today that Scott Winder has joined the firm’s Valuation Advisory Services Group as a Managing Director. Based in the San Francisco Bay Area, Mr. Winder will work with RNA’s other senior officers to deliver a comprehensive range of services including: market research, analytical modeling, valuation assessments, financial advisory consulting and transactional support for strategic deals and partnership opportunities. Mr. Winder specializes in providing tax and financial reporting-related valuation advisory services to the firm’s clients.
Mr. Winder joins RNA Advisors with over two decades of experience in the life sciences and financial services industries. Most recently, he served as the Co-Head of Private Market Valuation Services at Morgan Stanley at Work, where he advised clients in the biopharmaceutical, medical device and tools & diagnostics segments of the life sciences industry and also the enterprise hardware, business applications, ecommerce and digital content & media segments of the technology industry. Prior to that, he was the Co-Founder of Solium Analytics, a Senior Director at SVB Analytics where he led the life sciences practice, and a Manager at Deloitte Financial Advisory Services. Before his career in the financial advisory services industry, Mr. Winder was a scientist at two biotechnology companies focusing on gene expression technologies for diagnostic and genomic research applications.
“The RNA team is thrilled to welcome Scott to our Valuation Advisory Services Group,” said Sam Renwick, Founding Principal and CEO of RNA Advisors. “Scott has extensive experience overseeing numerous complicated valuation engagements and other impressive projects in the biopharmaceuticals, digital health and medical device sectors. His wealth of experience and knowledge, together with a deep commitment to achieving outstanding results for our clients, will prove invaluable to both growing our client base and leveraging RNA’s successful services platform.”
“I am personally particularly honored to be joining the team at RNA Advisors. RNA sets the standard when it comes to providing top quality advisory support to early stage and pre-commercial life sciences companies. I look forward to partnering with my new colleagues to deliver innovative solutions for the firm’s clients,” notes Mr. Winder.
About RNA Advisors
RNA Advisors is a leading financial advisory and valuation consulting firm focused exclusively in the life sciences and healthcare sectors. Since the firm’s founding in 2015, RNA Advisors has provided over 300 clients across life sciences and healthcare verticals with strategic decision analysis, valuation, and transactional support for 1700+ transactions worth over $282 billion in asset and transaction value. RNA assists life sciences and healthcare technology companies and investors by providing research, analysis and consulting support for highly strategic transactions, acquisitions, and commercial partnerships. RNA Advisors’ clients include private venture-backed and public companies in biotech, biopharmaceuticals, digital health, medical devices, healthcare services and technology, as well as royalty stream investors, potential joint venture partners, M&A transaction counterparties, financiers and licensors/licensees. RNA’s deeply experienced team includes 20+ consultants and analysts delivering high-level to deep-dive market assessments, market research, comparative valuation analyses, and financial modeling and forecasts which support decision making around corporate growth strategies. RNA Advisors also delivers end-to-end transaction support in the form of fairness opinions, intellectual property valuations, asset and enterprise valuations, drug royalty forecasts, derivative security valuations, pro forma capitalization table modeling, and gift/estate tax valuations for investors. Learn more about RNA Advisor client success stories at rnaadvisors.com.
